Self-reported Clinical Characteristics of Interview Participants Diagnosed With Mpox (May–October 2022), Seattle–King County, Washington
| Mpox Clinical Characteristics . | No. (%) . |
|---|---|
| Symptomsa | |
| Anal or genital sores | 84 (73.0) |
| Fatigue | 77 (67.0) |
| Fevers/chills | 66 (57.4) |
| Sores or bumps on trunk, extremities | 58 (50.4) |
| Sores in multiple places | 33 (28.9) |
| Sores or bumps on the face | 31 (27.0) |
| Sore throat | 30 (26.1) |
| Severe symptomsa | |
| Rectal pain/tenesmus/proctitis | 38 (33.0) |
| Rectal bleeding | 27 (23.5) |
| Severe pain requiring lidocaine or narcotics | 24 (20.9) |
| Penile swelling or phimosis | 21 (18.3) |
| Difficulty swallowing | 14 (12.2) |
| Concern for superinfection | 11 (9.6) |
| >100 lesions | n ≤ 10 (2.6) |
| Hospitalization | n ≤ 10 (2.6) |
| Scarring | 47 (40.9) |
| Mpox vaccination | |
| Unvaccinated | 55 (47.8) |
| Received at least 1 vaccination | 60 (52.2) |
| Vaccinated after onset of illness | 23 (20.0) |
| Received 1 vaccine within 7 d prior to onset (PEP) | 18 (15.6) |
| Received 1 vaccine ≥1 wk before onset | 17 (14.8) |
| Fully vaccinated before onset | 2 (1.7) |
| Tecovirimat therapy | |
| Received tecovirimat | 80 (69.6) |
| Received tecovirimat ≤5 d from onset (n = 80) | 43 (53.8) |
| Results-based therapy (n = 80) | 52 (65.0) |
| Presumptive therapy (n = 80) | 28 (35.0) |
| Completed 14 d of therapy (n = 80) | 74 (92.5) |
| Side effects of therapya | |
| Any side effect | 25 (31.3) |
| Headache | 10 (12.5) |
| Nausea | 9 (11.3) |
| Abdominal pain | 6 (7.5) |
| “Mental fog” | 6 (7.5) |
| Dizziness | 6 (7.5) |
| Diarrhea | 5 (6.3) |
| Mpox Clinical Characteristics . | No. (%) . |
|---|---|
| Symptomsa | |
| Anal or genital sores | 84 (73.0) |
| Fatigue | 77 (67.0) |
| Fevers/chills | 66 (57.4) |
| Sores or bumps on trunk, extremities | 58 (50.4) |
| Sores in multiple places | 33 (28.9) |
| Sores or bumps on the face | 31 (27.0) |
| Sore throat | 30 (26.1) |
| Severe symptomsa | |
| Rectal pain/tenesmus/proctitis | 38 (33.0) |
| Rectal bleeding | 27 (23.5) |
| Severe pain requiring lidocaine or narcotics | 24 (20.9) |
| Penile swelling or phimosis | 21 (18.3) |
| Difficulty swallowing | 14 (12.2) |
| Concern for superinfection | 11 (9.6) |
| >100 lesions | n ≤ 10 (2.6) |
| Hospitalization | n ≤ 10 (2.6) |
| Scarring | 47 (40.9) |
| Mpox vaccination | |
| Unvaccinated | 55 (47.8) |
| Received at least 1 vaccination | 60 (52.2) |
| Vaccinated after onset of illness | 23 (20.0) |
| Received 1 vaccine within 7 d prior to onset (PEP) | 18 (15.6) |
| Received 1 vaccine ≥1 wk before onset | 17 (14.8) |
| Fully vaccinated before onset | 2 (1.7) |
| Tecovirimat therapy | |
| Received tecovirimat | 80 (69.6) |
| Received tecovirimat ≤5 d from onset (n = 80) | 43 (53.8) |
| Results-based therapy (n = 80) | 52 (65.0) |
| Presumptive therapy (n = 80) | 28 (35.0) |
| Completed 14 d of therapy (n = 80) | 74 (92.5) |
| Side effects of therapya | |
| Any side effect | 25 (31.3) |
| Headache | 10 (12.5) |
| Nausea | 9 (11.3) |
| Abdominal pain | 6 (7.5) |
| “Mental fog” | 6 (7.5) |
| Dizziness | 6 (7.5) |
| Diarrhea | 5 (6.3) |
Abbreviation: PEP, postexposure prophylaxis.
aNot mutually exclusive.
Self-reported Clinical Characteristics of Interview Participants Diagnosed With Mpox (May–October 2022), Seattle–King County, Washington
| Mpox Clinical Characteristics . | No. (%) . |
|---|---|
| Symptomsa | |
| Anal or genital sores | 84 (73.0) |
| Fatigue | 77 (67.0) |
| Fevers/chills | 66 (57.4) |
| Sores or bumps on trunk, extremities | 58 (50.4) |
| Sores in multiple places | 33 (28.9) |
| Sores or bumps on the face | 31 (27.0) |
| Sore throat | 30 (26.1) |
| Severe symptomsa | |
| Rectal pain/tenesmus/proctitis | 38 (33.0) |
| Rectal bleeding | 27 (23.5) |
| Severe pain requiring lidocaine or narcotics | 24 (20.9) |
| Penile swelling or phimosis | 21 (18.3) |
| Difficulty swallowing | 14 (12.2) |
| Concern for superinfection | 11 (9.6) |
| >100 lesions | n ≤ 10 (2.6) |
| Hospitalization | n ≤ 10 (2.6) |
| Scarring | 47 (40.9) |
| Mpox vaccination | |
| Unvaccinated | 55 (47.8) |
| Received at least 1 vaccination | 60 (52.2) |
| Vaccinated after onset of illness | 23 (20.0) |
| Received 1 vaccine within 7 d prior to onset (PEP) | 18 (15.6) |
| Received 1 vaccine ≥1 wk before onset | 17 (14.8) |
| Fully vaccinated before onset | 2 (1.7) |
| Tecovirimat therapy | |
| Received tecovirimat | 80 (69.6) |
| Received tecovirimat ≤5 d from onset (n = 80) | 43 (53.8) |
| Results-based therapy (n = 80) | 52 (65.0) |
| Presumptive therapy (n = 80) | 28 (35.0) |
| Completed 14 d of therapy (n = 80) | 74 (92.5) |
| Side effects of therapya | |
| Any side effect | 25 (31.3) |
| Headache | 10 (12.5) |
| Nausea | 9 (11.3) |
| Abdominal pain | 6 (7.5) |
| “Mental fog” | 6 (7.5) |
| Dizziness | 6 (7.5) |
| Diarrhea | 5 (6.3) |
| Mpox Clinical Characteristics . | No. (%) . |
|---|---|
| Symptomsa | |
| Anal or genital sores | 84 (73.0) |
| Fatigue | 77 (67.0) |
| Fevers/chills | 66 (57.4) |
| Sores or bumps on trunk, extremities | 58 (50.4) |
| Sores in multiple places | 33 (28.9) |
| Sores or bumps on the face | 31 (27.0) |
| Sore throat | 30 (26.1) |
| Severe symptomsa | |
| Rectal pain/tenesmus/proctitis | 38 (33.0) |
| Rectal bleeding | 27 (23.5) |
| Severe pain requiring lidocaine or narcotics | 24 (20.9) |
| Penile swelling or phimosis | 21 (18.3) |
| Difficulty swallowing | 14 (12.2) |
| Concern for superinfection | 11 (9.6) |
| >100 lesions | n ≤ 10 (2.6) |
| Hospitalization | n ≤ 10 (2.6) |
| Scarring | 47 (40.9) |
| Mpox vaccination | |
| Unvaccinated | 55 (47.8) |
| Received at least 1 vaccination | 60 (52.2) |
| Vaccinated after onset of illness | 23 (20.0) |
| Received 1 vaccine within 7 d prior to onset (PEP) | 18 (15.6) |
| Received 1 vaccine ≥1 wk before onset | 17 (14.8) |
| Fully vaccinated before onset | 2 (1.7) |
| Tecovirimat therapy | |
| Received tecovirimat | 80 (69.6) |
| Received tecovirimat ≤5 d from onset (n = 80) | 43 (53.8) |
| Results-based therapy (n = 80) | 52 (65.0) |
| Presumptive therapy (n = 80) | 28 (35.0) |
| Completed 14 d of therapy (n = 80) | 74 (92.5) |
| Side effects of therapya | |
| Any side effect | 25 (31.3) |
| Headache | 10 (12.5) |
| Nausea | 9 (11.3) |
| Abdominal pain | 6 (7.5) |
| “Mental fog” | 6 (7.5) |
| Dizziness | 6 (7.5) |
| Diarrhea | 5 (6.3) |
Abbreviation: PEP, postexposure prophylaxis.
aNot mutually exclusive.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
